KAT2B and melanoma: HATs such as KAT1 (HAT1) and KAT2B (PCAF) have been identified to confirm the epigenetic impact in melanoma [179, 180], So that increasing the activation of the AKT signaling pathway gives rise to MAPKi resistance [181, 182].